secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001171843-24-004603
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex Q2 net loss $0.54 per share; Phase 3 CSU program launched
-----------------------------------------------------------------

- Net loss $35.8M ($0.54/share) vs $30.5M loss in Q2 2023; revenue $2.5M, up from $0.3M.
- Cash $802.3M as of June 30; sufficient to fund operations through 2027.
- Initiated global Phase 3 CSU trials (EMBARQ-CSU1/2) in July 2024; actively enrolling.
- Phase 2 CIndU study met primary endpoint (negative provocation test) at Week 12; full data 2H 2024.
- Barzolvolimab Phase 2 studies ongoing in PN, EoE; AD study to start YE 2024; bispecific CDX-622 enters clinic in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000117184324004603/0001171843-24-004603-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000117184324004603/f8k_080824.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-004603

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer